Jaguar supports evauation of FDA-approved crofelemer for GI issues from GLP-1

Jaguar Health (JAGX) family company Napo Pharmaceuticals, Napo announced Napo’s filing of a broad defining provisional patent application with the U.S. Patent and Trademark Office USPTO for crofelemer, Jaguar’s novel plant-based FDA-approved gastrointestinal normalizing prescription drug, to mitigate the gastrointestinal side effects associated with glucagon-like peptide-1 or GLP-1, eceptor agonists and antagonists, together with other incretin-based therapies including glucose-dependent insulinotropic polypeptide GIP agonists and antagonists, and glucagon-agonist drugs..”Gastrointestinal disorders were the most frequently reported adverse effects during clinical trials and real-world experience of GLP-1 receptor agonists, 2 such as semaglutide, tirzepatide, and liraglutide. GI adverse events usually develop in 40-70% of patients treated with GLP-1 receptor agonists, although they have sometimes been reported in up to 85%, 3 which can lead to dose limitations or dose discontinuations. There are also numerous investigative agents, including incretins and combinations with GLP-1 drugs, both as receptor agonists and antagonists, all of which are associated with significant GI side effects, often in a dose-dependent manner. Our IP strategy includes claims for both commercialized obesity drugs and incretin-based therapies in development. Crofelemer, approved by the U.S. Food and Drug Administration under the brand name Mytesi for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and discomfort, incontinence, bloating and constipation, when studied in populations with HIV-related diarrhea, cancer therapy-related diarrhea, and IBS,” said Lisa Conte, Jaguar’s founder, president, and CEO.